Vimarsana
Biggest News Aggregation in the World

Liver Fat News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Liver Fat. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Liver Fat Today - Breaking & Trending Today

BBCNEWS Breakfast July 5, 2024 - Vimarsana News

BBCNEWS Breakfast July 5, 2024

it will be mild. all the details later. it's thursday the 25th of january. our main story. the families of the victims of the nottingham attacks will find out today what sentence the killer will receive. valdo calocane stabbed university students grace o'malley—kumar and barnaby webber, both 19, before attacking 65—year—old school caretaker ian coates. his guilty plea to manslaughter on the grounds of diminished responsibility was accepted by the court earlier this week. our reporter navtej johal has spoken exclusively to ian's family ahead of today's sentencing. stubborn. yeah...

Pegozafermin Shows Sustained Benefit for NASH in Phase 2b Extension Study - Vimarsana News

Pegozafermin Shows Sustained Benefit for NASH in Phase 2b Extension Study

Results from the 24-week extension period of the phase 2b ENLIVEN trial showed sustained improvements in liver fat, fibrosis, and inflammation among those treated with 30 mg weekly and 44 mg biweekly pegozafermin.

Empagliflozin Reduces Liver Fat Content Regardless of T2DM, Study Finds - Vimarsana News

Empagliflozin Reduces Liver Fat Content Regardless of T2DM, Study Finds

Findings were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases and showed empagliflozin reduced liver fat content in both patients with T2DM and nondiabetic patients.

Hepatology Month in Review: October 2023 - Vimarsana News

Hepatology Month in Review: October 2023

Our October 2023 hepatology month in review features phase 2/3 data, updates in the hepatology pipeline, and other top news.

Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023 - Vimarsana News

Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023

Presentation Highlights Previously Reported Weight Loss of up to 7.8% From Baseline as well as Significant Liver Fat, Plasma Lipid Reductions following 28 Days of Treatment with VK2735 SAN DIEGO,...